Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam
Authors
Keywords
-
Journal
Frontiers in Microbiology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-07-20
DOI
10.3389/fmicb.2021.709974
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phenotypic and Molecular Characterisations of Carbapenem-resistant Acinetobacter baumannii Isolates Collected within the EURECA Study
- (2021) T Kostyanev et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens
- (2021) Jacob E Choby et al. LANCET INFECTIOUS DISEASES
- In vitro activity of sulbactam-durlobactam against extensive-drug-resistant Acinetobacter baumannii isolates belonging to South America major clones
- (2021) Carolina S. Nodari et al. Journal of Global Antimicrobial Resistance
- In vitro activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex isolates collected globally from 2016-2017
- (2020) Sarah M. McLeod et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical Pharmacokinetics and Pharmacodynamics of Imipenem–Cilastatin/Relebactam Combination Therapy
- (2020) Matthew W. McCarthy CLINICAL PHARMACOKINETICS
- In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China
- (2020) Qiwen Yang et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In Vitro Characterization of ETX1317, a Broad-Spectrum β-Lactamase Inhibitor That Restores and Enhances β-Lactam Activity against Multi-Drug-Resistant Enterobacteriales, Including Carbapenem-Resistant Strains
- (2020) Alita A. Miller et al. ACS Infectious Diseases
- In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii
- (2020) Harald Seifert et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
- (2020) Matteo Bassetti et al. LANCET INFECTIOUS DISEASES
- Interactions of the Diazabicyclooctane Serine β-Lactamase Inhibitor ETX1317 with Target Enzymes
- (2020) Adam B. Shapiro et al. ACS Infectious Diseases
- Ceftazidime–Avibactam Resistance Mutations V240G, D179Y, and D179Y/T243M in KPC-3 β-Lactamase Do Not Alter Cefpodoxime–ETX1317 Susceptibility
- (2020) Adam B. Shapiro et al. ACS Infectious Diseases
- Quantifying the Interactions between Biomolecules: Guidelines for Assay Design and Data Analysis
- (2019) Peter J Tonge ACS Infectious Diseases
- Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent
- (2019) Melissa D. Barnes et al. mBio
- Interplay between β-lactamases and new β-lactamase inhibitors
- (2019) Karen Bush et al. NATURE REVIEWS MICROBIOLOGY
- Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects
- (2019) John O'Donnell et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Prevalence of healthcare-associated infections and antimicrobial use in China: results from the 2018 point prevalence survey in 189 hospitals in Guangdong province
- (2019) Yu Zhang et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Multidrug Resistant Acinetobacter baumannii: Resistance by Any Other Name Would Still be Hard to Treat
- (2019) David A. Butler et al. Current Infectious Disease Reports
- Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis
- (2019) Olexiy Sagan et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
- (2018) Antoni Torres et al. LANCET INFECTIOUS DISEASES
- New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections
- (2018) Burcu Isler et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options
- (2017) Chang-Ro Lee et al. Frontiers in Cellular and Infection Microbiology
- Acinetobacter baumannii OmpA Is a Selective Antibiotic Permeant Porin
- (2017) Ramkumar Iyer et al. ACS Infectious Diseases
- Reversibility of Covalent, Broad-Spectrum Serine β-Lactamase Inhibition by the Diazabicyclooctenone ETX2514
- (2017) Adam B. Shapiro et al. ACS Infectious Diseases
- ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii
- (2017) Thomas F. Durand-Réville et al. Nature Microbiology
- Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges
- (2016) Darren Wong et al. CLINICAL MICROBIOLOGY REVIEWS
- Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014
- (2016) Lindsey M. Weiner et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Molecular Mechanisms of Sulbactam Antibacterial Activity and Resistance Determinants in Acinetobacter baumannii
- (2015) William F. Penwell et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam ‘enhancer’
- (2015) Akihiro Morinaka et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Acinetobacter baumannii: Evolution of Antimicrobial Resistance—Treatment Options
- (2015) Gerald Murray et al. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
- Contribution of Acinetobacter-derived cephalosporinase-30 to sulbactam resistance in Acinetobacter baumannii
- (2015) Shu-Chen Kuo et al. Frontiers in Microbiology
- Ampicillin/sulbactam: Its potential use in treating infections in critically ill patients
- (2013) Syamhanin Adnan et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- TEM-1 -lactamase as a source of resistance to sulbactam in clinical strains of Acinetobacter baumannii
- (2013) L. Krizova et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases
- (2013) David E. Ehmann et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Bacterial cytological profiling rapidly identifies the cellular pathways targeted by antibacterial molecules
- (2013) P. Nonejuie et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Avibactam is a covalent, reversible, non- -lactam -lactamase inhibitor
- (2012) D. E. Ehmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
- (2011) A.-P. Magiorakos et al. CLINICAL MICROBIOLOGY AND INFECTION
- Diversity, Epidemiology, and Genetics of Class D -Lactamases
- (2009) L. Poirel et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now